登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，7月30日，Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-08-19

  • Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
    Noe B. Mercado, Roland Zahn, […]Dan H. Barouch
    Nature (2020)

    Abstract
    A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1–8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.

  • 原文来源：https://www.nature.com/articles/s41586-020-2607-z
114浏览量
原文链接
相关报告

  • 《Nature，9月3日，Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-15
    • Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters Lisa H. Tostanoski, Frank Wegmann, […]Dan H. Barouch Nature Medicine (2020) Abstract Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death1,2,3,4. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters5,6,7 and nonhuman primates8,9,10 have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates11,12,13. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
    109浏览量
    原文链接

  • 《Science，5月20日，SARS-CoV-2 infection protects against rechallenge in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-21
    • SARS-CoV-2 infection protects against rechallenge in rhesus macaques View ORCID ProfileAbishek Chandrashekar1,*, View ORCID ProfileJinyan Liu1,*, View ORCID ProfileAmanda J. Martinot1,2,*, View ORCID ProfileKatherine McMahan1,*, View ORCID ProfileNoe B. Mercado1,*, View ORCID ProfileLauren Peter1,*, View ORCID ProfileLisa H. Tostanoski1,*, View ORCID ProfileJingyou Yu1,*, View ORCID ProfileZoltan Maliga3, Michael Nekorchuk4, View ORCID ProfileKathleen Busman-Sahay4, View ORCID ProfileMargaret Terry4, View ORCID ProfileLinda M. Wrijil2, View ORCID ProfileSarah Ducat2, David R. Martinez5, View ORCID ProfileCaroline Atyeo3,6, View ORCID ProfileStephanie Fischinger6, View ORCID ProfileJohn S. Burke6, View ORCID ProfileMatthew D. Slein6, View ORCID ProfileLaurent Pessaint7, View ORCID ProfileAlex Van Ry7, View ORCID ProfileJack Greenhouse7, View ORCID ProfileTammy Taylor7, View ORCID ProfileKelvin Blade7, Anthony Cook7, View ORCID ProfileBrad Finneyfrock7, Renita Brown7, Elyse Teow7, Jason Velasco7, View ORCID ProfileRoland Zahn8, View ORCID ProfileFrank Wegmann8, View ORCID ProfilePeter Abbink1, View ORCID ProfileEsther A. Bondzie1, View ORCID ProfileGabriel Dagotto1,3, View ORCID ProfileMakda S. Gebre1,3, Xuan He1, View ORCID ProfileCatherine Jacob-Dolan1,3, View ORCID ProfileNicole Kordana1, Zhenfeng Li1, View ORCID ProfileMichelle A. Lifton1, View ORCID ProfileShant H. Mahrokhian1, View ORCID ProfileLori F. Maxfield1, View ORCID ProfileRamya Nityanandam1, View ORCID ProfileJoseph P. Nkolola1, View ORCID ProfileAaron G. Schmidt6,9, View ORCID ProfileAndrew D. Miller10, View ORCID ProfileRalph S. Baric5, View ORCID ProfileGalit Alter6,9, View ORCID ProfilePeter K. Sorger3, View ORCID ProfileJacob D. Estes4, View ORCID ProfileHanne Andersen7, View ORCID ProfileMark G. Lewis7, View ORCID ProfileDan H. Barouch1,6,9,† See all authors and affiliations Science 20 May 2020: eabc4776 DOI: 10.1126/science.abc4776 Abstract An understanding of protective immunity to SARS-CoV-2 is critical for vaccine and public health strategies aimed at ending the global COVID-19 pandemic. A key unanswered question is whether infection with SARS-CoV-2 results in protective immunity against re-exposure. We developed a rhesus macaque model of SARS-CoV-2 infection and observed that macaques had high viral loads in the upper and lower respiratory tract, humoral and cellular immune responses, and pathologic evidence of viral pneumonia. Following initial viral clearance, animals were rechallenged with SARS-CoV-2 and showed 5 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa compared with primary infection. Anamnestic immune responses following rechallenge suggested that protection was mediated by immunologic control. These data show that SARS-CoV-2 infection induced protective immunity against re-exposure in nonhuman primates.
    107浏览量
    原文链接